BioSpace News Archive

Experienced executive will accelerate company’s growth in quickly developing market

Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced David P. Hochman, chairman, CEO and founder, will present at the Canaccord Genuity MedTech and Diagnostics Forum on November 21, 2019 and the 31st Annual Piper Jaffray Healthcare Conference on December 4, 2019.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of SRK-015 for the treatment of patients with spinal muscular atrophy (SMA).

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, yesterday announced the release of its HTG EdgeSeq Reveal data analysis software, version 2.0.0.

XSOLIS, the company channeling health care data into predictive intelligence and action, today announced that it has acquired MEDarchon, a provider of intelligent clinical communication.

A new virtual companion to the Thermo Scientific TruScan RM Handheld Raman Analyzer is available for pharmaceutical and biopharmaceutical manufacturers that continue to move toward more efficient modern digitization and cloud computing

ATCC, the world’s premier biological materials resource and standards organization, announced the appointment of Raymond D. Stapleton, Jr., PhD, to the role of President and Chief Operating Officer.

Webinar entitled: Continuous Health Action Engagement to Maximize Quality Improvement

Lucence, a genomic medicine company that invents blood-based tests for cancer screening and treatment selection, announced the close of USD $20 million in Series A funding.

Axonics Modulation Technologies, Inc. announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions.